BCL2L1 and Miyoshi myopathy: This kind of modified BCMA-targeted CAR-T cell has a higher BCL2L1 expression, and in MM cell lines (MM1S, OCMY5, and H929) expressing the ligands of FAS death receptor (FASLG), BCMA-BCL2L1-CAR-T cells observably outperformed unarmored BCMA-CAR-T cells in terms of viability and cytolysis activity.